The acquisition enhances DSM-Firmenich’s presence in several markets, including early-life nutrition, medical nutrition, and the microbiome market for pet health and animal feed.
DSM-Firmenich (Kaiseraugst, Switzerland; Heerlen, Netherlands) has completed the acquisition of Adare Biome (Lawrenceville, NJ), a developer of postbiotic ingredients, for €275 million. The acquisition enhances DSM-Firmenich’s presence in several markets, including early-life nutrition, medical nutrition, and the microbiome market for pet health and animal feed.
Specifically, DSM-Firmenich notes that through its B2C group i-Health, the company plans to expand the reach of Adare Biome’s Lactéol postbiotic supplement for relieving stomach upset.
“The Adare Biome teams will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals,” stated Philip Eykerman, president of Health, Nutrition, & Care at DSM-Firmenich, in a press release.
The company calls postbiotics “the next wave of opportunity in the gut health market,” stating that postbiotic ingredients offer longer shelf-life and broader application possibilities compared to probiotics.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.